|
CA2344208A1
(en)
|
2001-04-30 |
2002-10-30 |
Oxford Biomedica (Uk) Limited |
Method
|
|
US9738907B2
(en)
|
2002-02-01 |
2017-08-22 |
Oxford Biomedica (Uk) Limited |
Viral vector
|
|
DK1504108T3
(da)
*
|
2002-02-01 |
2013-06-10 |
Oxford Biomedica Ltd |
Lentivirusvektor
|
|
CA2475101A1
(en)
*
|
2002-02-04 |
2003-08-14 |
Novartis Ag |
Recombinant bovine immunodeficiency virus based gene transfer system
|
|
CN1980955A
(zh)
*
|
2004-04-29 |
2007-06-13 |
北卡罗来纳-查佩尔山大学 |
增强细胞粘连特性的方法和组合物
|
|
TW200613554A
(en)
|
2004-06-17 |
2006-05-01 |
Wyeth Corp |
Plasmid having three complete transcriptional units and immunogenic compositions for inducing an immune response to HIV
|
|
GB0526210D0
(en)
|
2005-12-22 |
2006-02-01 |
Oxford Biomedica Ltd |
Vectors
|
|
WO2009153563A1
(en)
|
2008-06-18 |
2009-12-23 |
Oxford Biomedica (Uk) Limited |
Virus purification
|
|
JP5965392B2
(ja)
|
2010-05-28 |
2016-08-03 |
オックスフォード バイオメディカ （ユーケー） リミテッド |
脳へのレンチウイルスベクターの送達
|
|
GB201118636D0
(en)
|
2011-10-28 |
2011-12-07 |
Oxford Biomedica Ltd |
Nucleotide sequence
|
|
EP2986635B1
(en)
|
2013-04-18 |
2018-10-03 |
Fondazione Telethon |
Effective delivery of large genes by dual aav vectors
|
|
WO2015059674A1
(en)
|
2013-10-24 |
2015-04-30 |
Ospedale San Raffaele S.R.L. |
Method
|
|
GB201322798D0
(en)
|
2013-12-20 |
2014-02-05 |
Oxford Biomedica Ltd |
Production system
|
|
MX378859B
(es)
|
2014-09-15 |
2025-03-11 |
Molmed Spa |
Receptores de antigenos quimericos.
|
|
GB201418965D0
(enExample)
|
2014-10-24 |
2014-12-10 |
Ospedale San Raffaele And Fond Telethon |
|
|
GB201519086D0
(en)
|
2015-10-28 |
2015-12-09 |
Syncona Partners Llp |
Gene Therapy
|
|
US20190017096A1
(en)
|
2016-03-10 |
2019-01-17 |
Nightstarx Limited |
Prenylation assay
|
|
EP3443001B1
(en)
|
2016-04-11 |
2025-04-30 |
Obsidian Therapeutics, Inc. |
REGULATED BIOCIRCUIT SYSTEMS
|
|
EP3235828A1
(en)
*
|
2016-04-21 |
2017-10-25 |
Genethon |
Stable pseudotyped lentiviral particles and uses thereof
|
|
EP3318285A1
(en)
|
2016-11-08 |
2018-05-09 |
Oxford University Innovation Limited |
Treatment of eye disease
|
|
CN109952377A
(zh)
|
2016-12-01 |
2019-06-28 |
雀巢产品技术援助有限公司 |
调节fam46a的方法
|
|
CN108130333A
(zh)
*
|
2016-12-01 |
2018-06-08 |
上海泽润生物科技有限公司 |
重组脊髓灰质炎ⅰ型病毒样颗粒
|
|
EP3375876A1
(en)
|
2017-03-13 |
2018-09-19 |
Evonetix Ltd |
Method for producing double stranded polynucleotides based on oligonucleotides with selected and different melting temperatures
|
|
AU2018235130B2
(en)
|
2017-03-15 |
2023-12-07 |
Oxford Biomedica (Uk) Limited |
Method
|
|
EP3601566A1
(en)
|
2017-03-31 |
2020-02-05 |
Société des Produits Nestlé S.A. |
Methods of modulating ank1
|
|
GB201706121D0
(en)
*
|
2017-04-18 |
2017-05-31 |
Glaxosmithkline Ip Dev Ltd |
Stable cell lines for retroviral production
|
|
EP4491233A3
(en)
|
2017-04-21 |
2025-04-16 |
Ospedale San Raffaele S.r.l. |
Gene therapy
|
|
IL270084B2
(en)
|
2017-04-24 |
2026-03-01 |
Ospedale San Raffaele Srl |
TCR binding peptide from WILMS TUMOUR 1 protein and its use in cancer therapy
|
|
WO2019068854A1
(en)
|
2017-10-06 |
2019-04-11 |
Ospedale San Raffaele S.R.L. |
GENE THERAPY OF NEURODEGENERATIVE DISEASES USING VAA VECTORS
|
|
EP3697923A1
(en)
|
2017-10-17 |
2020-08-26 |
Nightstarx Limited |
Prenylation assay
|
|
JP7477448B2
(ja)
|
2017-11-21 |
2024-05-01 |
ソシエテ・デ・プロデュイ・ネスレ・エス・アー |
Ａｌｋを調節する方法
|
|
GB201720948D0
(en)
|
2017-12-15 |
2018-01-31 |
Autolus Ltd |
Plasmid system
|
|
EP3696272A1
(en)
|
2017-12-22 |
2020-08-19 |
Oxford BioMedica (UK) Limited |
Retroviral vector
|
|
WO2019134866A1
(en)
|
2018-01-03 |
2019-07-11 |
Molmed Spa |
Chimeric antigen receptors containing optimal spacer region
|
|
CN112004924A
(zh)
|
2018-04-18 |
2020-11-27 |
Ucl商务有限公司 |
增强treg细胞抑制特性的方法
|
|
MX2020012295A
(es)
|
2018-05-15 |
2021-03-31 |
Flagship Pioneering Innovations V Inc |
Composiciones de fusosoma y usos de estas.
|
|
WO2019219308A1
(en)
|
2018-05-17 |
2019-11-21 |
Societe Des Produits Nestle S.A. |
Methods of modulating nkx6.3
|
|
KR20210016567A
(ko)
|
2018-05-30 |
2021-02-16 |
글리코스템 떼라퓨틱스 비.브이. |
Car nk 세포
|
|
WO2020014209A1
(en)
|
2018-07-09 |
2020-01-16 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions and uses thereof
|
|
GB201814203D0
(en)
|
2018-08-31 |
2018-10-17 |
King S College London |
Engineered regulatory t cell
|
|
GB201817821D0
(en)
|
2018-10-31 |
2018-12-19 |
Ospedale San Raffaele Srl |
TCR and peptides
|
|
CA3120082A1
(en)
|
2018-11-14 |
2020-05-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for cns delivery
|
|
WO2020102503A2
(en)
|
2018-11-14 |
2020-05-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for t cell delivery
|
|
WO2020102485A1
(en)
|
2018-11-14 |
2020-05-22 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions for hematopoietic stem cell delivery
|
|
AU2019400930A1
(en)
|
2018-12-19 |
2021-07-01 |
King's College London |
Immunotherapeutic methods and compositions
|
|
GB201900687D0
(en)
|
2019-01-17 |
2019-03-06 |
King S College London |
Immunotherapeutic methods and compositions
|
|
GB201902277D0
(en)
|
2019-02-19 |
2019-04-03 |
King S College London |
Therapeutic agents
|
|
CA3133188A1
(en)
|
2019-03-10 |
2020-09-17 |
Oxford Biomedica (Uk) Limited |
Gene therapy compositions and methods for treating parkinson's disease
|
|
GB201905301D0
(en)
|
2019-04-15 |
2019-05-29 |
Ospedale San Raffaele Srl |
Gene therapy
|
|
GB201907493D0
(en)
|
2019-05-28 |
2019-07-10 |
Ospedale San Raffaele |
Agents and methods for treating viral infections
|
|
GB201912515D0
(en)
|
2019-08-30 |
2019-10-16 |
King S College London |
Engineered regulatory T cell
|
|
AU2020341454A1
(en)
|
2019-09-03 |
2022-03-10 |
Sana Biotechnology, Inc. |
CD24-associated particles and related methods and uses thereof
|
|
KR20220097492A
(ko)
|
2019-11-12 |
2022-07-07 |
옥스포드 바이오메디카(유케이) 리미티드 |
생산 시스템
|
|
JP2023513303A
(ja)
|
2020-02-13 |
2023-03-30 |
オックスフォード バイオメディカ（ユーケー）リミテッド |
レンチウイルスベクターの製造
|
|
US20230138428A1
(en)
|
2020-02-25 |
2023-05-04 |
Quell Therapeutics Limited |
Chimeric receptors for use in engineered cells
|
|
US20230118587A1
(en)
|
2020-03-13 |
2023-04-20 |
Oxford Biomedica (Uk) Limited |
Lentiviral Vectors
|
|
EP4127144A1
(en)
|
2020-03-31 |
2023-02-08 |
Sana Biotechnology, Inc. |
Targeted lipid particles and compositions and uses thereof
|
|
GB202007169D0
(en)
|
2020-05-14 |
2020-07-01 |
Ospedale San Raffaele Srl |
Epidermal growth factor receptor
|
|
GB202007199D0
(en)
|
2020-05-15 |
2020-07-01 |
Oxford Biomedica Ltd |
Viral vector production
|
|
US20230190871A1
(en)
|
2020-05-20 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and compositions for treatment of viral infections
|
|
GB202013477D0
(en)
|
2020-08-27 |
2020-10-14 |
Quell Therapeutics Ltd |
Nucleic acid constructs for expressing polypeptides in cells
|
|
US20230303665A1
(en)
|
2020-08-28 |
2023-09-28 |
Sana Biotechnology, Inc. |
Modified anti-viral binding agents
|
|
GB202017725D0
(en)
|
2020-11-10 |
2020-12-23 |
Oxford Biomedica Ltd |
Method
|
|
GB202018657D0
(en)
|
2020-11-26 |
2021-01-13 |
Ospedale San Raffaele Srl |
Agents and methods for increasing liver immune response
|
|
CN112430582B
(zh)
*
|
2020-12-04 |
2022-05-03 |
北京艺妙神州医药科技有限公司 |
一种慢病毒稳定包装细胞系及其制备方法
|
|
WO2022136874A1
(en)
|
2020-12-23 |
2022-06-30 |
Quell Therapeutics Limited |
Inducible signalling protein
|
|
CA3204161A1
(en)
|
2021-01-11 |
2022-07-14 |
Jagesh Vijaykumar SHAH |
Use of cd8-targeted viral vectors
|
|
CA3207166A1
(en)
|
2021-02-01 |
2022-08-04 |
Angelo Leone Lombardo |
Gene silencing
|
|
US20240101623A1
(en)
|
2021-02-15 |
2024-03-28 |
Ospedale San Raffaele S.R.L. |
Epigenetic silencing for treatment of cancer
|
|
GB202102637D0
(en)
|
2021-02-24 |
2021-04-07 |
Quell Therapeutics Ltd |
Engineered regulatory t cell
|
|
GB202102832D0
(en)
*
|
2021-02-26 |
2021-04-14 |
Ip2Ipo Innovations Ltd |
Retroviral vectors
|
|
CN117377771A
(zh)
|
2021-05-12 |
2024-01-09 |
特莱索恩基金会 |
载体系统
|
|
WO2022251712A1
(en)
|
2021-05-28 |
2022-12-01 |
Sana Biotechnology, Inc. |
Lipid particles containing a truncated baboon endogenous retrovirus (baev) envelope glycoprotein and related methods and uses
|
|
US20240344083A1
(en)
|
2021-08-04 |
2024-10-17 |
Sana Biotechnology, Inc. |
Use of cd4-targeted viral vectors
|
|
WO2023047098A2
(en)
|
2021-09-21 |
2023-03-30 |
Quell Therapeutics Ltd |
Anti-p75ntr chimeric antigen receptor
|
|
US20240390422A1
(en)
|
2021-09-21 |
2024-11-28 |
Quell Therapeutics Limited |
Anti-trem2 chimeric antigen receptor
|
|
GB202114528D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114534D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Novel viral regulatory elements
|
|
GB202114530D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Retroviral vectors
|
|
GB202114529D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
GB202114532D0
(en)
|
2021-10-12 |
2021-11-24 |
Oxford Biomedica Ltd |
Lentiviral Vectors
|
|
US20250230511A1
(en)
|
2021-10-29 |
2025-07-17 |
Sana Biotechnology, Inc. |
Methods and reagents for amplifying viral vector nucleic acid products
|
|
GB202117298D0
(en)
|
2021-11-30 |
2022-01-12 |
Quell Therapeutics Ltd |
Signalling protein
|
|
GB202117844D0
(en)
|
2021-12-09 |
2022-01-26 |
Oxford Biomedica Ltd |
Purification method
|
|
WO2023114949A1
(en)
|
2021-12-16 |
2023-06-22 |
Sana Biotechnology, Inc. |
Methods and systems of particle production
|
|
US20250059239A1
(en)
|
2021-12-17 |
2025-02-20 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
WO2023118878A1
(en)
|
2021-12-22 |
2023-06-29 |
Quell Therapeutics Limited |
Constitutive cytokine receptors
|
|
EP4209511A1
(en)
|
2022-01-05 |
2023-07-12 |
Gyala Therapeutics Sociedad Limitada |
Anti-cd84 antibodies amd chimeric antigen receptors
|
|
AU2023205629A1
(en)
|
2022-01-05 |
2024-08-15 |
Fundació De Recerca Clinic Barcelona-Institut D’Investigacions Biomèdiques August Pi I Sunyer |
Anti-cd84 antibodies and chimeric antigen receptors
|
|
WO2023133595A2
(en)
|
2022-01-10 |
2023-07-13 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4472646A1
(en)
|
2022-02-01 |
2024-12-11 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
WO2023150647A1
(en)
|
2022-02-02 |
2023-08-10 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
US20250222027A1
(en)
|
2022-04-01 |
2025-07-10 |
Sana Biotechnology, Inc. |
Cytokine receptor agonist and viral vector combination therapies
|
|
EP4269426A1
(en)
|
2022-04-29 |
2023-11-01 |
Ospedale San Raffaele S.r.l. |
Gene therapy
|
|
EP4303226A1
(en)
|
2022-07-08 |
2024-01-10 |
Ospedale San Raffaele S.r.l. |
Transgene cassettes and epigenetic silencers for the treatment of disorders
|
|
US20260000790A1
(en)
|
2022-07-08 |
2026-01-01 |
Ospedale San Raffaele S.R.L. |
Transgene cassettes
|
|
US20260027145A1
(en)
|
2022-07-27 |
2026-01-29 |
Sana Biotechnology, Inc. |
Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
|
|
WO2024033544A1
(en)
|
2022-08-12 |
2024-02-15 |
Ospedale San Raffaele S.R.L. |
Deglycosylation of native glycoproteins expressed on a tumor cell surface
|
|
GB202211935D0
(en)
|
2022-08-16 |
2022-09-28 |
Oxford Biomedica Ltd |
envelope proteins
|
|
US20260055146A1
(en)
|
2022-08-24 |
2026-02-26 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
WO2024064838A1
(en)
|
2022-09-21 |
2024-03-28 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
WO2024081820A1
(en)
|
2022-10-13 |
2024-04-18 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024100145A1
(en)
|
2022-11-08 |
2024-05-16 |
Ospedale San Raffaele S.R.L. |
Polynucleotide and vector
|
|
CN120882745A
(zh)
|
2022-11-11 |
2025-10-31 |
圣拉斐尔医院有限责任公司 |
Cdh17 car
|
|
GB202217541D0
(en)
|
2022-11-24 |
2023-01-11 |
Quell Therapeutics Ltd |
Recombinant receptor
|
|
WO2024119157A1
(en)
|
2022-12-02 |
2024-06-06 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024133472A1
(en)
|
2022-12-22 |
2024-06-27 |
Quell Therapeutics Limited |
Constitutive cytokine receptors
|
|
EP4651887A1
(en)
|
2023-01-16 |
2025-11-26 |
Ospedale San Raffaele S.r.l. |
T-cell receptors
|
|
EP4403580A1
(en)
|
2023-01-23 |
2024-07-24 |
Medizinische Hochschule Hannover |
Anti-entpd3 chimeric antigen receptor
|
|
TW202436337A
(zh)
|
2023-01-23 |
2024-09-16 |
漢諾威醫學院 |
嵌合抗原受體
|
|
AU2024219048A1
(en)
|
2023-02-07 |
2025-08-07 |
Quell Therapeutics Limited |
Culture method for treg cells
|
|
EP4669343A1
(en)
|
2023-02-24 |
2025-12-31 |
Medizinische Hochschule Hannover |
CHIMERIC ANTIGEN RECIPIENT
|
|
EP4420676A1
(en)
|
2023-02-24 |
2024-08-28 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
EP4680728A1
(en)
|
2023-03-17 |
2026-01-21 |
Quell Therapeutics Limited |
Treg therapy
|
|
WO2024194223A2
(en)
|
2023-03-17 |
2024-09-26 |
Ospedale San Raffaele S.R.L. |
Gene therapy
|
|
CN121586582A
(zh)
|
2023-03-20 |
2026-02-27 |
汉诺威医学院 |
嵌合抗原受体
|
|
EP4434539A1
(en)
|
2023-03-20 |
2024-09-25 |
Medizinische Hochschule Hannover |
Chimeric antigen receptor
|
|
CN121219020A
(zh)
|
2023-03-22 |
2025-12-26 |
圣拉斐尔医院有限责任公司 |
基因疗法
|
|
WO2024194649A1
(en)
|
2023-03-22 |
2024-09-26 |
Quell Therapeutics Limited |
Engineered t cells and uses thereof
|
|
WO2024194642A1
(en)
|
2023-03-22 |
2024-09-26 |
Quell Therapeutics Limited |
Engineered t regulatory cell
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
WO2024220597A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Digital droplet based assay for detecting replication competent lentiviral vector
|
|
GB202307366D0
(en)
|
2023-05-17 |
2023-06-28 |
Ospedale San Raffaele Srl |
Vector
|
|
AU2024274792A1
(en)
|
2023-05-23 |
2025-10-23 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
WO2024261480A1
(en)
|
2023-06-21 |
2024-12-26 |
Quell Therapeutics Limited |
Constitutive cytokine receptors
|
|
AU2024305679A1
(en)
|
2023-06-28 |
2026-01-22 |
Ospedale San Raffaele S.R.L. |
T-cell receptors
|
|
WO2025032194A1
(en)
|
2023-08-08 |
2025-02-13 |
Ospedale San Raffaele S.R.L. |
T-cell receptors
|
|
IT202300022191A1
(it)
|
2023-10-24 |
2025-04-24 |
Fond Telethon Ets |
Mezzi e metodi per la modifica genetica di uba1
|
|
GB202316264D0
(en)
|
2023-10-24 |
2023-12-06 |
Ospendale San Raffaele S R L |
Gene therapy
|
|
WO2025109189A1
(en)
|
2023-11-24 |
2025-05-30 |
Ospedale San Raffaele S.R.L. |
Engineered regulatory t cells and uses thereof
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
EP4640830A1
(en)
|
2024-04-23 |
2025-10-29 |
Fondazione Telethon ETS |
Means and methods for safe and efficient gene editing in cells
|
|
WO2026008994A1
(en)
|
2024-07-04 |
2026-01-08 |
Quell Therapeutics Limited |
Expression construct
|
|
WO2026027876A1
(en)
|
2024-07-29 |
2026-02-05 |
Quell Therapeutics Limited |
Chimeric antigen receptor
|
|
GB202411558D0
(en)
|
2024-08-06 |
2024-09-18 |
Quell Therapeutics Ltd |
Culture method
|
|
GB202415025D0
(en)
|
2024-10-11 |
2024-11-27 |
Ospedale San Raffaele Srl |
Cell
|
|
WO2026088097A1
(en)
|
2024-10-24 |
2026-04-30 |
Fondazione Telethon Ets |
Mutation-independent genome editing
|